Palker 125 mg (Capsule)
Unit Price: ৳ 400.00 (1 x 21: ৳ 8,400.00)
Strip Price: ৳ 8,400.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Palbociclib |
| Company | Beacon pharmaceuticals plc |
Indications
- Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer
- Used in combination with aromatase inhibitor or fulvestrant
- For postmenopausal women
- For women with disease progression following endocrine therapy
Pharmacology
- Inhibitor of Cyclin-dependent kinases (CDK) 4 and 6
- Reduces cellular proliferation of ER-positive breast cancer cell lines
- Blocks progression of the cell from G1 into S phase of the cell cycle
- Leads to decreased retinoblastoma (RB) protein phosphorylation
- Results in reduced E2F expression and signaling
- Increases cell senescence in ER-positive breast cancer cell lines
- Demonstrated effectiveness in patient-derived ER-positive breast cancer xenograft model
Dosage & Administration
- Recommended dose: 125 mg capsule taken orally once daily for 21 consecutive days
- Followed by 7 days off treatment to comprise a complete cycle of 28 days
- Should be taken with food
- Recommended starting dose: 125 mg/day
- First dose reduction: 100 mg/day
- Second dose reduction: 75 mg/day
- Use in children: Not indicated
Interaction
- Primarily metabolized by CYP3A and SULT enzyme SULT2A1
- Time-dependent inhibitor of CYP3A
- Agents that may increase plasma concentrations of Palker
- Agents that may decrease plasma concentrations of Palker
- Drugs that may have their plasma concentrations altered by Palker
Side Effects
- Common side effects include WBC decreased, infections, fatigue, nausea, hair loss, diarrhea, anemia, rash, weakness, vomiting, dry skin, fever
Pregnancy & Lactation
- Can cause fetal harm when administered to a pregnant woman
- Risk of major birth defects and miscarriage in clinically recognized pregnancies
Precautions & Warnings
- Neutropenia: Most frequently reported adverse reaction
- Median time to first episode of any grade neutropenia was 15 days
- Severe, life-threatening, fatal interstitial lung disease (ILD)/pneumonitis can occur
- Embryo fetal toxicity: Can cause fetal harm when administered to a pregnant woman
Overdose Effects
- No known antidote
- Treatment should consist of general supportive measures
Therapeutic Class
- Protein kinase inhibitor
Storage Conditions
- Keep below 30°C temperature
- Away from light & moisture
- Keep out of the reach of children